ACADIA Pharmaceuticals (NASDAQ:ACAD) : During the past 4 weeks, traders have been relatively bearish on ACADIA Pharmaceuticals (NASDAQ:ACAD), hence the stock is down -13.96% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -0.2% relative to the S&P 500. The stock has risen by 1.08% in the past week indicating that the buyers are active at lower levels, but the stock is down -12.58% in the past 4 weeks.
The company shares have dropped -22.71% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $51.99 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $35.67 and the 200 Day Moving Average price is recorded at $28.39.
The stock has recorded a 20-day Moving Average of 1.46% and the 50-Day Moving Average is 2.34%.
ACADIA Pharmaceuticals (NASDAQ:ACAD): stock turned positive on Friday. Though the stock opened at $33.59, the bulls momentum made the stock top out at $34.84 level for the day. The stock recorded a low of $33.05 and closed the trading day at $34.62, in the green by 3.31%. The total traded volume for the day was 1,824,984. The stock had closed at $33.51 in the previous days trading.
In an insider trading activity,The (EVP AND GC) of Acadia Pharmaceuticals Inc, Baity Glenn sold 7,000 shares at $20.8 on March 2, 2016. The Insider selling transaction had a total value worth of $145,600. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for the treatment of neurological and related central nervous system disorders. The Companys drug candidate NUPLAZID (pimavanserin) is under development for the treatment of Parkinsons disease psychosis, Alzheimers disease psychosis, Schizophrenia and Sleep disturbances. The Company is also conducting preclinical programs for alpha adrenergic agonists indicated for the treatment of chronic pain and muscarinic drugs for the treatment of glaucoma. NUPLAZID has an active ingredient pimavanserin, is a selective serotonin inverse agonist (SSIA) preferentially targeting 5-HT2A receptors that was discovered by the Company. The Company in collaboration with Allergan, has discovered and engaged in the development of small-molecule product candidates, such as alpha adrenergic agonists and muscarinic receptors.